KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma

被引：0

作者：

Ascierto, P. A. ^{[1
]}

Ferrucci, P. F. ^{[2
]}

Stephens, R. ^{[3
]}

Del Vecchio, M. ^{[4
]}

Atkinson, V. ^{[5
]}

Schmidt, H. ^{[6
]}

Schachter, J. ^{[7
]}

Queirolo, P. ^{[8
]}

Long, G. V. ^{[9
]}

Di Giacomo, A. M. ^{[10
]}

Svane, I. ^{[11
]}

Lotem, M. ^{[12
]}

Bar-Sela, G. ^{[13
]}

Couture, F. ^{[14
]}

Mookerjee, B. P. ^{[15
]}

Ghori, R. ^{[16
]}

Ibrahim, N. ^{[16
]}

Moreno, B. Homet ^{[16
]}

Ribas, A. ^{[17
]}

机构：

[1] Ist Nazl Tumori Fdn G Pascale, Melanoma Canc Immunotherapy & Dev Therapeut Unit, Naples, Italy

[2] Ist Europeo Oncol, Oncol, Milan, Italy

[3] Auckland City Hosp, Med Oncol, Auckland, New Zealand

[4] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy

[5] Greenslopes Private Hosp, Gallipoli Med Res Fdn, Med Oncol, Brisbane, Qld, Australia

[6] Aarhus Univ Hosp, Oncol, Aarhus, Denmark

[7] Sheba Med Ctr Tel HaShomer, Ctr Canc, Inst Oncol, Oncol,Ella Lemelbaum Inst Melanoma, Ramat Gan, Israel

[8] IRCCS San Martino IST, Oncol Med, Genoa, Italy

[9] Univ Sydney, Melanoma Inst Australia, Med Oncol, Sydney, NSW, Australia

[10] Univ Hosp Siena, Ctr Immunooncol, Med Oncol, Siena, Italy

[11] Univ Copenhagen, Herlev Hosp, Oncol, Herlev, Denmark

[12] Hadassah Hebrew Med Ctr, Sharett Inst Oncol, Med Oncol, Jerusalem, Israel

[13] Rambam Hlth Care Campus, Oncol, Haifa, Israel

[14] Laval Univ, Ctr Hosp Univ Quebec Res Ctr, Hematol, Quebec City, PQ, Canada

[15] Novartis, Oncol Clin Dev, E Hanover, NJ USA

[16] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA

[17] Ronald Reagan UCLA Med Ctr, Med Oncol, Los Angeles, CA USA

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1244O

引用

页码：442 / 442

页数：1

共 50 条

[1] Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: Phase 1 KEYNOTE-022 study
Ribas, Antoni
Hodi, F. Stephen
Lawrence, Donald P.
Atkinson, Victoria
Starodub, Alexander
Carlino, Matteo S.
Fisher, Rosalie Anne
Long, Georgina V.
Miller, Wilson H.
Huang, Yingjie
Diede, Scott J.
Ebbinghaus, Scot
Hamid, Omid
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[2] KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma
Ribas, A.
Hodi, F. S.
Lawrence, D.
Atkinson, V.
Agarwal, S.
Carlino, M. S.
Fisher, R.
Long, G. V.
Miller, W. H.
Huang, Y.
Moreno, B. Homet
Ibrahim, N.
Hamid, O.
ANNALS OF ONCOLOGY, 2017, 28
[3] Phase 2 randomized study of 1L dabrafenib and trametinib plus pembrolizumab or placebo for BRAF-mutant advanced melanoma
Ascierto, Paolo A.
Ferrucci, Pier F.
Stephens, Rosalie
Del Vecchio, Michele
Atkinson, Victoria
Schmidt, Henrik
Schachter, Jacob
Queirolo, Paola
Long, Georgina V.
Di Giacomo, Anna Maria
Svane, Inge
Lotem, Michal
Bar-Sela, Gil
Couture, Felix
Mookerjee, Bijoyesh P.
Ghori, Razi
Ibrahim, Nageatte
Moreno, Blanca Homet
Ribas, Antoni
JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17
[4] KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
Ferrucci, Pier Francesco
Di Giacomo, Anna Maria
Del Vecchio, Michele
Atkinson, Victoria
Schmidt, Henrik
Schachter, Jacob
Queirolo, Paola
Long, Georgina, V
Stephens, Rosalie
Svane, Inge Marie
Lotem, Michal
Abu-Amna, Mahmoud
Gasal, Eduard
Ghori, Razi
Diede, Scott J.
Croydon, Elizabeth S.
Ribas, Antoni
Ascierto, Paolo Antonio
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[5] Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022).
Long, Georgina V.
Hamid, Omid
Hodi, F. Stephen
Lawrence, Donald P.
Atkinson, Victoria
Starodub, Alexander
Carlino, Matteo S.
Fisher, Rosalie Anne
Miller, Wilson H.
Maio, Michele
Butler, Marcus
Queirolo, Paola
Ferrucci, Pier Francesco
Petrella, Teresa M.
Schachter, Jacob
Huang, Yingjie
Diede, Scott J.
Ebbinghaus, Scot
Ribas, Antoni
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[6] KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma (vol 8, e001806, 2020)
Ferrucci, P. F.
Di Giacomo, A. M.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (11)
[7] Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAFV600E/Kmutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.
Ribas, Antoni
Ferrucci, Pier Francesco
Atkinson, Victoria
Stephens, Rosalie
Long, Georgina V.
Lawrence, Donald P.
Del Vecchio, Michele
Hamid, Omid
Schmidt, Henrik
Schachter, Jacob
Queirolo, Paola
Miller, Wilson H.
Carlino, Matteo S.
Di Giacomo, Anna Maria
Svane, Inge Marie
Ghori, Razi
Singh, Rohini
Diede, Scott J.
Ascierto, Paolo Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[8] NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D plus T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy.
Long, Georgina V.
Carlino, Matteo S.
Au-Yeung, George
Spillane, Andrew John
Shannon, Kerwin Frank
Gyorki, David E.
Howle, Julie R.
Ch'ng, Sydney
Gonzalez, Maria
Saw, Robyn P. M.
Pennington, Thomas
Lo, Serigne N.
Scolyer, Richard A.
Menzies, Alexander M.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[9] Niraparib plus Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study
Ramalingam, S.
Arora, S.
Neibauer, M. Whipple
Zhou, J.
Hazard, S.
Frenkl, T.
Stojadinovic, A.
Peters, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S653 - S654
[10] Randomized phase II trial (PORTSIDE) evaluating encorafenib (enco) and binimetinib (bini) plus pembrolizumab (pembro) versus nivolumab (nivo) and ipilimumab (ipi) for the treatment of advanced BRAF-mutant melanoma
Schadendorf, D.
Dummer, R.
Ribas, A.
Robert, C.
Sullivan, R. J.
King, A.
Polli, A.
di Pietro, A.
Ascierto, P. A.
ANNALS OF ONCOLOGY, 2023, 34 : S700 - S700

← 1 2 3 4 5 →